These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35028272)

  • 1. Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.
    Vaisbich MH; Caires Ferreira J; Price H; Young KD; Sile S; Checani G; Langman CB
    JIMD Rep; 2022 Jan; 63(1):66-79. PubMed ID: 35028272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").
    Langman CB
    Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
    Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
    J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
    van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
    Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
    Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
    Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of cystinosis in children with twice-daily cysteamine.
    Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
    J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.
    Belldina EB; Huang MY; Schneider JA; Brundage RC; Tracy TS
    Br J Clin Pharmacol; 2003 Nov; 56(5):520-5. PubMed ID: 14651726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
    Dohil R; Cabrera BL
    Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
    Medic G; van der Weijden M; Karabis A; Hemels M
    Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.
    Klank S; van Stein C; Grüneberg M; Ottolenghi C; Rauwolf KK; Grebe J; Reunert J; Harms E; Marquardt T
    Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
    Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
    J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients.
    Kishk OA; Kim I; Cheng C; Summan M; Muñoz MA
    Pediatr Nephrol; 2024 Aug; 39(8):2429-2433. PubMed ID: 38462547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
    Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
    BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules.
    Pavloff N; Hauser TA; Williams C; Isbell SL; Cadieux B; Johnson M
    Drug Des Devel Ther; 2018; 12():2795-2804. PubMed ID: 30233142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.
    Lashilola S; Xu W; Azimpour K; McCarthy M; Carlot S; Game D; van der Voort J
    BMC Nephrol; 2023 Nov; 24(1):351. PubMed ID: 38031005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.